GSK expands rare diseases
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline continued its foray into rare diseases by signing an exclusive deal with Amicus Therapeutics to develop and commercialise Amigal (migalastat HCI) which is being developed to treat Fabry disease, while also taking a 20% stake in the US biotech. This is the second deal GSK has signed since it outlined its rare diseases strategy to Scrip earlier this month (scripintelligence.com, 12 October 2010). Last week, GSK signed a gene therapy pact with the San Raffaele Telethon Institute for Gene Therapy (scripintelligence.com, 18 October, 2010).